High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer - PubMed (original) (raw)
Clinical Trial
. 2002 Nov;11(11):1492-5.
Affiliations
- PMID: 12433733
Clinical Trial
High pretreatment serum concentration of basic fibroblast growth factor is a predictor of poor prognosis in small cell lung cancer
Tarja Ruotsalainen et al. Cancer Epidemiol Biomarkers Prev. 2002 Nov.
Abstract
Basic fibroblast growth factor (bFGF) is a secreted multifunctional cytokine and a potent stimulator of angiogenesis. We measured bFGF concentrations from serum samples taken from 103 patients with small cell lung cancer at the time of diagnosis. Serum concentration of bFGF (S-bFGF) ranged from undetectable to 54 pg/ml (median, 6 pg/ml). S-bFGF was not associated with age, sex, performance status, or stage. A high pretreatment S-bFGF was associated with poor overall survival. The 1- and 2-year survival rates of the patients within the highest quartile of S-bFGF (>or=17 pg/ml) were only 26% and 11%, respectively, in contrast to the 49% and 20% 1- and 2-year survival rates of those patients with S-bFGF < 17 pg/ml (P = 0.013). The 1- and 2-year survival rates of the patients with extensive-stage disease were 33% and 10%, respectively (P = 0.0091). Interestingly, S-bFGF provided additional prognostic information to the stage because the 1- and 2-year survival rates of patients with extensive-stage disease and a high S-bFGF (>or=17 pg/ml) were as low as 16% and 5%, respectively (P = 0.0026). Similarly, in the multivariate model of survival analysis, patients with both extensive-stage disease and a high S-bFGF (>or=17 pg/ml) were found to have a particularly poor prognosis (relative risk of death, 2.1; 95% confidence interval, 1.2-3.6; P = 0.0057). We conclude that a high S-bFGF at diagnosis is associated with poor outcome in small cell lung cancer, possibly reflecting active angiogenesis and rapid tumor growth, and may complement prognostic information obtained by staging.
Similar articles
- Soluble syndecan-1 and serum basic fibroblast growth factor are new prognostic factors in lung cancer.
Joensuu H, Anttonen A, Eriksson M, Mäkitaro R, Alfthan H, Kinnula V, Leppä S. Joensuu H, et al. Cancer Res. 2002 Sep 15;62(18):5210-7. Cancer Res. 2002. PMID: 12234986 - Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) levels, as prognostic indicators in NSCLC.
Iwasaki A, Kuwahara M, Yoshinaga Y, Shirakusa T. Iwasaki A, et al. Eur J Cardiothorac Surg. 2004 Mar;25(3):443-8. doi: 10.1016/j.ejcts.2003.11.031. Eur J Cardiothorac Surg. 2004. PMID: 15019676 - Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease.
Kyrtsonis MC, Vassilakopoulos TP, Siakantaris MP, Kokoris SI, Gribabis DA, Dimopoulou MN, Angelopoulou MK, Pangalis GA. Kyrtsonis MC, et al. Eur J Haematol. 2004 Apr;72(4):252-8. doi: 10.1046/j.0902-4441.2003.00205.x. Eur J Haematol. 2004. PMID: 15089762 - Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood.
Bremnes RM, Camps C, Sirera R. Bremnes RM, et al. Lung Cancer. 2006 Feb;51(2):143-58. doi: 10.1016/j.lungcan.2005.09.005. Epub 2005 Dec 19. Lung Cancer. 2006. PMID: 16360975 Review.
Cited by
- Targeted Therapies in Small Cell Lung Cancer: From Old Failures to Novel Therapeutic Strategies.
Cani M, Napoli VM, Garbo E, Ferrari G, Del Rio B, Novello S, Passiglia F. Cani M, et al. Int J Mol Sci. 2023 May 17;24(10):8883. doi: 10.3390/ijms24108883. Int J Mol Sci. 2023. PMID: 37240229 Free PMC article. Review. - Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials.
Niu Z, Jin R, Zhang Y, Li H. Niu Z, et al. Signal Transduct Target Ther. 2022 Oct 5;7(1):353. doi: 10.1038/s41392-022-01200-x. Signal Transduct Target Ther. 2022. PMID: 36198685 Free PMC article. Review. - Increased serum concentrations of estrogen-induced growth factors Midkine and FGF2 in NF1 patients with plexiform neurofibroma.
Atallah I, Cieza Rivera AM, Rivero Lezcano OM, Tascón-González L, González-Cortés C, Diez Tascón C, Fernández-Villa T, Martín V. Atallah I, et al. Am J Transl Res. 2022 May 15;14(5):3180-3188. eCollection 2022. Am J Transl Res. 2022. PMID: 35702135 Free PMC article. - Fibroblast Growth Factor Receptors (FGFRs) and Noncanonical Partners in Cancer Signaling.
Ferguson HR, Smith MP, Francavilla C. Ferguson HR, et al. Cells. 2021 May 14;10(5):1201. doi: 10.3390/cells10051201. Cells. 2021. PMID: 34068954 Free PMC article. Review. - Small Cell Lung Cancer from Traditional to Innovative Therapeutics: Building a Comprehensive Network to Optimize Clinical and Translational Research.
Subbiah S, Nam A, Garg N, Behal A, Kulkarni P, Salgia R. Subbiah S, et al. J Clin Med. 2020 Jul 30;9(8):2433. doi: 10.3390/jcm9082433. J Clin Med. 2020. PMID: 32751469 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical